Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CYRAMZA vs VEGZELMA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ramucirumab is a human Ig G1 monoclonal antibody that binds to vascular endothelial growth factor receptor 2 (VEGFR-2) and blocks the interaction between VEGFR-2 and its ligands, VEGF-A, VEGF-C, and VEGF-D, thereby inhibiting receptor activation and subsequent angiogenesis.
VEGZELMA (bevacizumab-awwb) is a humanized monoclonal antibody that binds to vascular endothelial growth factor (VEGF) and inhibits VEGF receptor binding, thereby reducing angiogenesis and tumor vascularization.
Gastric or gastroesophageal junction adenocarcinoma, as monotherapy or with paclitaxel,Non-small cell lung cancer (NSCLC), in combination with docetaxel,Metastatic colorectal cancer, in combination with FOLFIRI,Hepatocellular carcinoma (HCC), as monotherapy,Off-label: Advanced urothelial carcinoma, endometrial cancer
Metastatic colorectal cancer (first-line with IFL regimen),Metastatic colorectal cancer (first-line with FOLFOX regimen),Metastatic colorectal cancer (second-line with FOLFOX),Non-squamous non-small cell lung cancer (first-line with carboplatin/paclitaxel),Glioblastoma (as single agent for progressive disease following prior therapy),Metastatic renal cell carcinoma (with interferon alfa),Cervical cancer (with paclitaxel/cisplatin or paclitaxel/topotecan),Platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (with paclitaxel, pegylated liposomal doxorubicin, or topotecan),Platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (with carboplatin/paclitaxel or carboplatin/gemcitabine)
8 mg/kg intravenously every 2 weeks or 10 mg/kg intravenously every 2 weeks if used in combination with paclitaxel or FOLFIRI.
Intravenous infusion, 240 mg every 2 weeks or 480 mg every 4 weeks.
Terminal elimination half-life is approximately 14 days (range 11–17 days) at steady state, supporting a dosing interval of every 2 weeks.
Terminal half-life: 11-14 hours (supports twice-daily dosing; no significant accumulation with normal renal function)
Ramucirumab is a monoclonal antibody; metabolism is via catabolism into small peptides and amino acids (nonspecific proteolytic degradation). No major metabolic enzymes involved.
Bevacizumab undergoes proteolytic degradation via general protein catabolism; no specific metabolic enzymes are involved.
Ramucirumab is eliminated primarily via proteolytic catabolism; no renal or biliary excretion occurs. Clearance is 0.014 L/h (0.022 L/h with high VEGF), with a mean terminal half-life of 14 days (range 11–17 days) at steady state.
Renal: 70% (metabolites); Fecal: 30% (unchanged drug and metabolites)
Approximately 95% bound to serum proteins, primarily albumin and immunoglobulins.
97% (primarily to albumin; minimal binding to alpha-1-acid glycoprotein)
Volume of distribution at steady state is approximately 5.0–6.0 L, corresponding to 0.07–0.09 L/kg (assuming 70 kg body weight), indicating limited extravascular distribution primarily within plasma volume.
0.3-0.5 L/kg (indicates limited extravascular distribution, primarily confined to plasma and interstitial fluid)
Bioavailability is 100% as ramucirumab is administered only by intravenous infusion; no oral or other form is available.
Subcutaneous: 60-80% (compared to intravenous); oral: not available (not orally bioavailable)
No dose adjustment recommended for mild to moderate renal impairment (Cr Cl >=30 m L/min). Not studied in severe renal impairment or dialysis.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min).
No dose adjustment recommended for mild hepatic impairment (Child-Pugh A). For moderate (Child-Pugh B) and severe (Child-Pugh C) hepatic impairment, no dosing information available; use with caution.
No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not studied in moderate or severe hepatic impairment (Child-Pugh B or C).
Safety and efficacy not established in pediatric patients.
Safety and efficacy not established in pediatric patients.
No dose adjustment required based on age. Monitor for increased risk of adverse events such as hypertension, hemorrhage, and gastrointestinal perforations.
No specific dose adjustment required; monitor for increased incidence of adverse reactions, particularly hypertension and infusion-related reactions.
Hemorrhage: Severe or fatal hemorrhage, including gastrointestinal hemorrhage, hemoptysis, and intracranial hemorrhage, has occurred. Do not administer in patients with severe bleeding.
Serious and sometimes fatal gastrointestinal perforation, wound dehiscence, hemorrhage, and arterial thromboembolic events (including stroke, myocardial infarction) have been reported. Therapy should be discontinued in patients who develop these complications.
Hemorrhage risk: Serious and sometimes fatal hemorrhagic events; permanently discontinue if severe bleeding occurs.,Arterial thromboembolic events: Including myocardial infarction and stroke; discontinue if occurs.,Gastrointestinal perforation: Fatal cases reported; discontinue if occurs.,Impaired wound healing: Interrupt therapy 28 days prior to elective surgery; do not resume until wound fully healed.,Hypertension: Monitor blood pressure; treat with antihypertensives; temporarily withhold if severe hypertension occurs.,Proteinuria: Monitor urine protein; withhold for >2 g/24h; discontinue if nephrotic syndrome develops.,Hypersensitivity/infusion reactions: Permanently discontinue if severe reaction occurs.,Thyroid dysfunction: Monitor thyroid function during treatment.
Gastrointestinal perforation; surgery and wound healing complications (discontinue at least 28 days prior to elective surgery); hemorrhage (severe/fatal pulmonary hemorrhage in NSCLC); arterial thromboembolic events; proteinuria; hypertensive crisis; posterior reversible encephalopathy syndrome; infusion reactions; increased risk of ovarian failure; congestive heart failure.
Severe hemorrhage (active bleeding),Hypersensitivity to ramucirumab or any excipients
None known.
No specific food interactions are documented. Avoid grapefruit juice if taking concomitant drugs metabolized by CYP3A4 (e.g., simvastatin) due to potential interaction, but no direct interaction with ramucirumab.
No specific food interactions. Maintain adequate hydration. Avoid grapefruit juice if also taking CYP3A4 substrates (though not directly studied with VEGZELMA).
Cyramza (ramucirumab) is a VEGF receptor antagonist. Based on its mechanism of action and animal studies, it can cause fetal harm when administered to pregnant women. In animal reproduction studies, intravenous administration of ramucirumab to pregnant rabbits during organogenesis resulted in embryofetal mortality and reduced fetal weight at exposures less than the recommended human dose. There are no adequate and well-controlled studies in pregnant women. Cyramza is contraindicated in pregnancy. First trimester: High risk of teratogenicity; VEGF inhibition interferes with embryonic vascular development. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and potential for fetal renal impairment due to anti-angiogenic effects. Avoid use during pregnancy.
VEGZELMA (bevacizumab-awwb) is a VEGF inhibitor. Based on mechanism of action and findings in animal studies (rabbits at doses ≥10 mg/kg every 3 days), there is evidence of teratogenicity including increased rates of fetal malformations (e.g., cleft palate, skeletal abnormalities) and embryofetal mortality. In humans, first trimester exposure is not recommended due to risk of teratogenicity. Second and third trimester exposure may be associated with fetal growth restriction, oligohydramnios, and potential fetal renal impairment. No adequate human studies exist; use only if benefit justifies risk.
No human data available on the presence of ramucirumab in human milk, effects on the breastfed infant, or effects on milk production. Ramucirumab is a large protein molecule (Ig G1 monoclonal antibody) and is likely to be present in breast milk at low levels, especially in early postpartum period. However, because of the potential for serious adverse reactions in the breastfed infant, advise women not to breastfeed during treatment and for at least 2 months after the last dose. M/P ratio: Not determined.
No human data on presence in breast milk. Bevacizumab is a large protein (MW ~149 k Da), likely to be excreted in low amounts. M/P ratio unknown. Potential for absorption and systemic effects in infant is low but cannot be excluded. Manufacturer advises to discontinue breastfeeding during therapy and for at least 6 months after last dose.
Cyramza is contraindicated in pregnancy; no dosing adjustments are recommended as use should be avoided. If used inadvertently, no specific pharmacokinetic data in pregnancy are available; however, physiological changes (e.g., increased plasma volume, altered renal function) may affect drug clearance, but no dose adjustment guidelines exist. The risk of fetal harm outweighs any potential benefit, and treatment should be discontinued immediately if pregnancy occurs.
No established dose adjustments for pregnancy. Due to risks, avoid use in pregnancy unless benefit outweighs risk. If used, dose remains same as for non-pregnant adults (e.g., 5 mg/kg IV every 2 weeks). Monitor for increased clearance in second and third trimester; however, no formal PK studies in pregnancy. Consider therapeutic drug monitoring if available.
CYRAMZA (ramucirumab) is a VEGFR-2 antagonist; premedicate with antihistamines and acetaminophen before infusion to reduce infusion-related reactions. Monitor blood pressure closely as hypertension is common; hold for severe hypertension. Avoid use in patients with significant bleeding risk or recent thromboembolic events. Do not administer with platinum-based chemotherapy in NSCLC patients with EGFR or ALK mutations unless progression on targeted therapy.
VEGZELMA (bevacizumab-adcd) is a bevacizumab biosimilar. Monitor blood pressure regularly due to risk of hypertension. Assess urine protein via dipstick before each dose; hold for ≥2 g proteinuria. Increased risk of arterial thromboembolic events (ATE) in patients >65 years or with prior ATE. Do not administer within 28 days of major surgery. Discontinue for GI perforation, wound dehiscence, or severe hemorrhage.
You may experience high blood pressure; monitor regularly and report symptoms like severe headache or vision changes.,This drug can increase bleeding risk; inform your doctor if you have any unusual bruising or bleeding.,Infusion reactions may occur; you will receive premedication to reduce this risk.,Report any new or worsening shortness of breath, chest pain, or leg swelling as these could be signs of blood clots or heart problems.,Wound healing may be impaired; avoid elective surgery during treatment and inform all healthcare providers you are on this medication.,Effective contraception is required during treatment and for at least 3 months after final dose.
Report any new or worsening hypertension, severe headache, or blurred vision.,Notify your doctor if you experience unusual bleeding, bruising, or blood in urine or stool.,Avoid invasive dental procedures and inform your dentist about this medication.,Use reliable contraception during treatment and for at least 6 months after the last dose.,Seek immediate medical attention for sudden chest pain, shortness of breath, or leg swelling.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CYRAMZA vs VEGZELMA, answered by our medical review team.
CYRAMZA is a Antineoplastic Monoclonal Antibody that works by Ramucirumab is a human Ig G1 monoclonal antibody that binds to vascular endothelial growth factor receptor 2 (VEGFR-2) and blocks the interaction between VEGFR-2 and its ligands, VEGF-A, VEGF-C, and VEGF-D, thereby inhibiting receptor activation and subsequent angiogenesis.. VEGZELMA is a Antineoplastic Monoclonal Antibody that works by VEGZELMA (bevacizumab-awwb) is a humanized monoclonal antibody that binds to vascular endothelial growth factor (VEGF) and inhibits VEGF receptor binding, thereby reducing angiogenesis and tumor vascularization.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CYRAMZA and VEGZELMA depend on the specific clinical indication. These are both Antineoplastic Monoclonal Antibody agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CYRAMZA is: 8 mg/kg intravenously every 2 weeks or 10 mg/kg intravenously every 2 weeks if used in combination with paclitaxel or FOLFIRI.. The standard adult dose of VEGZELMA is: Intravenous infusion, 240 mg every 2 weeks or 480 mg every 4 weeks.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CYRAMZA and VEGZELMA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CYRAMZA is classified as Category C. Cyramza (ramucirumab) is a VEGF receptor antagonist. Based on its mechanism of action and animal studies, it can cause fetal harm when administered to pregnant women. In animal rep. VEGZELMA is classified as Category C. VEGZELMA (bevacizumab-awwb) is a VEGF inhibitor. Based on mechanism of action and findings in animal studies (rabbits at doses ≥10 mg/kg every 3 days), there is evidence of teratog. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.